Trial Search Results

Identification of Key Blood Molecular Markers for Immunotherapy

To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Procedure: phlebotomy

Phase:

N/A

Eligibility


Inclusion Criteria:

   1. Patients diagnosed with cancerous tumors based on biopsy or other clinical
   observations.

   2. Patients diagnosed with non-cancerous tumors based on biopsy or other clinical
   observations.

   3. Normal volunteers who do not have cancer or other medical conditions that may affect
   survival.

Exclusion Criteria:

   1. Patients will be excluded if, upon clinical observation, they are under a severe
   septic or inflammatory condition. In these conditions, human body immune response
   against sepsis or inflammation should be the predominant response, and may shield or
   block the immune response against tumors.

   2. Patients will be excluded if, upon clinical observation, they are under extremely
   illness situation like myocardial infarction. In such a case, the immune findings may
   be altered.

   3. Patients will be excluded if, upon looking through their medical records, significant
   information required for data analysis is missing. This is because that patients'
   medical records will help us connect our research findings with their clinical
   observations, and further provide guidelines for subsequent treatment options.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kangla Tsung
650-725-8198
Not Recruiting